digid GmbH
Dr. Konstantin Kloppstech has extensive work experience in various roles and positions. Dr. Konstantin started their career as a Research Associate at Carl von Ossietzky Universität Oldenburg in December 2008, where they worked until September 2010. Dr. Konstantin then returned to the same university in October 2011 as a Researcher PhD Student, and they remained in this role until October 2015.
In 2016, Dr. Kloppstech held two simultaneous positions. Dr. Konstantin served as the Head of Technology at NanoScale Systems (Nanoss) GmbH from February 2016 to June 2019. Simultaneously, they also worked as the Technical Director and Project Manager at cantiMED UG (haftungsbeschränkt) from November 2016 to June 2019.
In August 2019, Dr. Kloppstech took on the role of International Operating Consultant, but the company name is not provided.
Currently, they work as the CTO at digid GmbH, a position they started in December 2019.
Dr. Konstantin Kloppstech pursued their education in physics from 2004 to 2011 at the Carl von Ossietzky University of Oldenburg, where they obtained a Diplom degree.
This person is not in any teams
digid GmbH
digid is developing a new kind of diagnostics healthcare platform solution through a proprietary combination of sensorics, biotech, A.I. and software that will, for the first time enable real-time identification of different biomarkers.At the very core of digid ´s development, is a proprietary biosensor in combination with specifically designedreceptors and digid´s Healthtech App as well as a fully integrated, A.I. powered Data Platform for real-time diagnostics of multiple human biomarkers.This custom, real-time diagnostics procedure enables the identification of multiple human biomarkers in real-time and gives users / patients personalized recommendations on how to improve the current state of wellbeing. This can be a recommended doctor visit with a subsequent therapeutical treatment, specific nutritional supplements or other personalized recommendations to improve wellbeing and the current health-state.Based on our proprietary